title: Leukotriene receptors on human pulmonary vascular endothelium.
abstract: 1. Cysteinyl-leukotrienes cause contractions and/or relaxations of human isolated pulmonary vascular preparations. Although, the localization and nature of the receptors through which these effects are mediated have not been fully characterized, some effects are indirect and not mediated via the well-described LT1 receptor. 2. In human pulmonary veins (HPV) with an intact endothelium, leukotriene D4 (LTD4) induced contraction above basal tone. This response was observed at lower concentrations of LTD4 in the presence of nitric oxide synthase inhibitor N omega-nitro-L-arginine (L-NOARG). Contractions (in the absence and presence of L-NOARG) were partially blocked by the LT1 antagonists (MK 571 and ICI 198615). 3. LTD4 relaxed HPV previously contracted with noradrenaline. This relaxation was potentiated by LT1 antagonists, but was abolished by removal of the endothelium. LTD4 also relaxed human pulmonary arteries (HPA) precontracted with noradrenaline but this effect was not modified by LT1 antagonists. 4. The results suggest that contraction of endothelium-intact HPV by LTD4 is partially mediated via LT1 receptors. Further, in endothelium-intact HPV, this contraction was opposed by a relaxation induced by LTD4, dependent on the release of nitric oxide, which was mediated, at least in part, via a non-LT1 receptor. In addition, LTD4 relaxation on contracted HPA was not mediated by LT1 receptors. 5. The mechanical effects of LTD4 on human pulmonary vasculature are complex and involve both direct and indirect mechanisms mediated via at least two types of cysteinyl-leukotriene receptors.
authors.affiliation: Department de Farmacologia, Universitat de Valencia, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Ortiz
authors.forename: I
authors.initials: I
authors.lastname: Gorenne
authors.forename: J
authors.initials: J
authors.lastname: Cortijo
authors.forename: A
authors.initials: A
authors.lastname: Seller
authors.forename: C
authors.initials: C
authors.lastname: Labat
authors.forename: B
authors.initials: B
authors.lastname: Sarria
authors.forename: T S
authors.initials: TS
authors.lastname: Abram
authors.forename: P J
authors.initials: PJ
authors.lastname: Gardiner
authors.forename: E
authors.initials: E
authors.lastname: Morcillo
authors.forename: C
authors.initials: C
authors.lastname: Brink
mesh_terms: D000704:Analysis of Variance; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000737:chemistry* / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D017998:Leukotriene D4 / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000737:chemistry* / Q000187:drug effects; D019335:Nitroarginine; D009638:Norepinephrine / Q000494:pharmacology; D011651:Pulmonary Artery / Q000187:drug effects / Q000378:metabolism; D011667:Pulmonary Veins / Q000737:chemistry* / Q000187:drug effects; D018077:Receptors, Leukotriene / Q000032:analysis*; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D018077:Receptors, Leukotriene; D019335:Nitroarginine; D017998:Leukotriene D4; D001120:Arginine; D009638:Norepinephrine